Rocket Pharmaceuticals (RCKT) Stock Rises On Gene Therapy Advancement
After obtaining a significant regulatory designation, investor confidence in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) surged. Thursday saw a 16.78% increase in RCKT shares, which ended the trading day at $3.34. The momentum comes after the U.S. Food and Drug Administration (FDA) announced that Rocket’s gene therapy candidate, RP-A601, has been designated as a Regenerative Medicine […]